lansoprazole and Recrudescence studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Research Excerpts

Excerpt	Relevance	Reference
"Esomeprazole, 20 mg once daily, is more effective than lansoprazole, 15 mg once daily, in maintaining remission in patients with healed reflux oesophagitis."	10.20	Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. ( Bayerdörffer, E; Bigard, MA; De Freitas, D; Devière, J; Eklund, S; Fried, M; Kristjánsdóttir, S; Larkö, A; Lauritsen, K; Morris, J; Mózsik, G; Murray, F; Orive, V; Rodrigo, L; Savarino, V; Schneider, H; Vetvik, K, 2003)
" lansoprazole in patients with erosive oesophagitis (EE), and to establish its long-term safety and efficacy as maintenance therapy."	9.22	Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. ( Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E, 2016)
"The clinical safety of long-term lansoprazole therapy for the maintenance of healed erosive oesophagitis has not been extensively studied in clinical trials."	9.14	The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2009)
"Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo."	9.11	Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005)
"This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer."	9.09	Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001)
"Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer-related symptoms."	9.09	Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1999)
"To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly."	9.09	Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. ( Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D, 1999)
"Lansoprazole, 15, 30, and 60 mg, administered once daily before eating, healed gastric ulcers to an approximately equal degree, and all were significantly better than placebo."	9.08	Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. ( Avner, DL; Berry, W; Erfling, W; McFarland, M; Movva, R; Nelson, KJ, 1995)
"Patients with an oesophageal stricture were randomized to receive either lansoprazole 30 mg once daily or high-dose ranitidine 300 mg twice daily for 12 months."	9.08	Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. ( Christian, J; Foster, CS; Garrett, AD; Gough, AL; Langworthy, CH; Swarbrick, ET, 1996)
"The proton-pump inhibitor, lansoprazole, a more potent gastric acid inhibitor with a longer action than H2-receptor antagonists, should heal refractory gastric ulcers more effectively."	9.08	A trial of lansoprazole in refractory gastric ulcer. ( Girdwood, AH; Louw, JA; Marks, IN; Simjee, AE; van Rensburg, CJ, 1996)
"This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients."	9.08	Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995)
"After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded."	9.08	Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997)
"Our purpose was to compare the safety and efficacy of lansoprazole 15 mg and 30 mg with placebo in preventing recurrence in 49 patients with a history of gastric ulcer."	9.08	Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1998)
"The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated."	9.08	Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995)
"Lansoprazole maintains its greater efficacy vs ranitidine even when administered at bedtime, both for the healing and for the maintenance treatment of duodenal ulcer."	9.08	Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. ( Dattilo, M; Russo, A, 1997)
"In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated."	9.08	The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995)
" In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer."	9.07	Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992)
"Time to ulcer recurrence was significantly longer (P < 0."	6.68	Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Jhala, N; Lanza, F; Silvers, D; Winters, J, 1997)
"Lansoprazole has a wide margin of safety and is well tolerated when administered as monotherapy in short- and long-term clinical trials."	6.41	Lansoprazole for maintenance of remission of erosive oesophagitis. ( Ballard, ED; Freston, JW; Huang, B; Jackson, RL, 2002)
"Esomeprazole, 20 mg once daily, is more effective than lansoprazole, 15 mg once daily, in maintaining remission in patients with healed reflux oesophagitis."	6.20	Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. ( Bayerdörffer, E; Bigard, MA; De Freitas, D; Devière, J; Eklund, S; Fried, M; Kristjánsdóttir, S; Larkö, A; Lauritsen, K; Morris, J; Mózsik, G; Murray, F; Orive, V; Rodrigo, L; Savarino, V; Schneider, H; Vetvik, K, 2003)
" Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer)."	5.34	Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. ( Chan, FKL; Ching, JYL; Chiu, PWY; Lau, JYW; Lau, LHS; Ling, RHY; Tse, YK; Wong, GLH; Wong, VWS, 2020)
"Vonoprazan (10 and 20 mg) was as effective as lansoprazole (15 mg) in preventing peptic ulcer recurrence during LDA therapy, had a similar long-term safety profile and was well tolerated."	5.27	Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. ( Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K, 2018)
"To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use."	5.27	Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. ( Ashida, K; Funao, N; Kawai, T; Mizokami, Y; Nishimura, A; Oda, K; Soen, S; Sugano, K, 2018)
" lansoprazole in patients with erosive oesophagitis (EE), and to establish its long-term safety and efficacy as maintenance therapy."	5.22	Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. ( Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E, 2016)
"The clinical safety of long-term lansoprazole therapy for the maintenance of healed erosive oesophagitis has not been extensively studied in clinical trials."	5.14	The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2009)
"Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment."	5.11	Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005)
"Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo."	5.11	Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005)
" In addition, more patients receiving celecoxib developed dyspepsia than patients receiving lansoprazole and naproxen."	5.11	Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, J; Wong, WM, 2005)
"Lansoprazole safely and effectively reduces duodenal ulcer recurrence and ulcer-related symptoms."	5.09	Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1999)
" Patients with gastric ulcer (GU) or duodenal ulcer (DU) were enrolled in this study; 583 eligible patients (GU, 325; DU, 258) were administered lansoprazole (30 mg/day for 8 weeks for GU, and the same dosage for 6 weeks for DU) as first-line therapy, and a half dose of H2RA as maintenance therapy for 12 months."	5.09	Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. ( Asaka, M; Asaki, S; Ashida, K; Harasawa, S; Hoshihara, Y; Kajiyama, G; Kaneko, E; Kobayashi, K; Muto, Y; Nakamura, T; Nakazawa, S; Ogawa, N; Sakaki, N; Takemoto, T; Yao, T, 2000)
"This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer."	5.09	Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001)
"To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly."	5.09	Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. ( Bardhan, KD; Crouch, SL; Crowe, J; Keeling, PN; Thompson, RP; Trewby, PN; Weir, D, 1999)
"Lansoprazole, 15, 30, and 60 mg, administered once daily before eating, healed gastric ulcers to an approximately equal degree, and all were significantly better than placebo."	5.08	Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. ( Avner, DL; Berry, W; Erfling, W; McFarland, M; Movva, R; Nelson, KJ, 1995)
"Lansoprazole maintains its greater efficacy vs ranitidine even when administered at bedtime, both for the healing and for the maintenance treatment of duodenal ulcer."	5.08	Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. ( Dattilo, M; Russo, A, 1997)
"In the present study, the effects of short-term treatment with lansoprazole on healing and recurrence of peptic ulcer were investigated."	5.08	The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. ( Akimoto, K; Fukujin, H; Katoaka, A; Mashima, H; Mine, T; Nagasawa, J; Tajima, A; Takano, T; Tsuchida, T; Yasuda, H, 1995)
"Our purpose was to compare the safety and efficacy of lansoprazole 15 mg and 30 mg with placebo in preventing recurrence in 49 patients with a history of gastric ulcer."	5.08	Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer. ( Campbell, D; Haber, M; Jennings, DE; Kovacs, TO; Richter, J; Rose, P, 1998)
"The clinical usefulness of lansoprazole in the healing of gastric and duodenal ulcers, the S2-stage shift rate (white scarring rate), and endoscopic healing rate with respect to degree of gastric mucosal atrophy were investigated."	5.08	Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. ( Asaki, S; Hongo, M; Sakurada, H; Sato, A; Takeda, T; Toyota, T, 1995)
"In patients with active or a recent history of duodenal ulcer, a 14-day course of lansoprazole-based triple therapy without additional acid suppression therapy is highly effective in the eradication of H."	5.08	Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. ( Freston, J; Haber, M; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A, 1998)
"After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded."	5.08	Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997)
"In order to investigate whether chronic duodenal ulcer disease is a consequence of disturbed mucosal turnover and growth factor expression, we studied 16 patients with duodenal ulcers before, during, and after endoscopic healing with lansoprazole or sucralfate."	5.08	Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans. ( Marks, IN; O'Keefe, SJ; Ogden, J; Winter, T; Zhang, T, 1998)
"This study attempted to determine the efficacy of lansoprazole plus clarithromycin therapy in the eradication of Helicobacter pylori in gastric ulcer patients."	5.08	Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. ( Aisawa, T; Akagi, T; Fukuda, S; Fukushi, M; Mizuki, I; Munakata, A; Ohkawa, K; Sakata, Y; Shimoyama, T; Yoshida, Y, 1995)
"Patients with an oesophageal stricture were randomized to receive either lansoprazole 30 mg once daily or high-dose ranitidine 300 mg twice daily for 12 months."	5.08	Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. ( Christian, J; Foster, CS; Garrett, AD; Gough, AL; Langworthy, CH; Swarbrick, ET, 1996)
"The proton-pump inhibitor, lansoprazole, a more potent gastric acid inhibitor with a longer action than H2-receptor antagonists, should heal refractory gastric ulcers more effectively."	5.08	A trial of lansoprazole in refractory gastric ulcer. ( Girdwood, AH; Louw, JA; Marks, IN; Simjee, AE; van Rensburg, CJ, 1996)
" In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer."	5.07	Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992)
"Aim of this overview was to evaluate the main clinical trials with lansoprazole published from 1997 to 1999 in English-language journals, regarding gastroesophageal reflux disease, peptic ulcer, NSAID-induced ulcer, and ZES."	4.80	[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. ( Capurso, L; Dobrilla, G, 2000)
" The dose of lansoprazole needed to heal the esophagitis was not significantly associated with the risk for clinical relapse (hazard ratio [HR] 1."	3.80	High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents. ( Brito, HS; Kawakami, E; Machado, RS; Ogata, SK; Yamamoto, E, 2014)
"Rates of EE recurrence during the 24-wk maintenance period were 16."	2.87	Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. ( Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E, 2018)
"Recurrence was significantly associated with study site (P = ."	2.78	Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. ( Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M, 2013)
"Relapse is infrequent and generally mild with acid secreting status closely monitored."	2.75	Costs and risks in the management of patients with gastric acid hypersecretion. ( Fineberg, N; Hirschowitz, BI; Mohnen, J; Wilcox, CM; Worthington, J, 2010)
"In patients who had ulcer complications related to the long-term use of low-dose aspirin, treatment with lansoprazole in addition to the eradication of H."	2.70	Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. ( Chan, AO; Chu, KM; Hu, WH; Hui, WM; Lai, CL; Lai, KC; Lam, SK; Lau, GK; Wong, BC; Wong, J; Wong, WM; Yuen, MF, 2002)
"pylori infection and the ulcer recurrence rate after 1 year were investigated."	2.68	Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. ( Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Koshiyama, T; Kudo, M; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H, 1996)
"Time to ulcer recurrence was significantly longer (P < 0."	2.68	Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. ( Goff, J; Greski-Rose, P; Jennings, D; Jhala, N; Lanza, F; Silvers, D; Winters, J, 1997)
"We investigated the eradication and recurrence rate of Helicobacter pylori-infected gastric ulcer patients by combination therapies."	2.68	Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. ( Fukuda, Y; Okui, M; Shimoyama, T; Tonokatsu, Y; Yamamoto, I, 1995)
"Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms."	2.68	Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. ( Avner, D; Haber, M; Lanza, F; Robinson, M, 1996)
"Lansoprazole has a wide margin of safety and is well tolerated when administered as monotherapy in short- and long-term clinical trials."	2.41	Lansoprazole for maintenance of remission of erosive oesophagitis. ( Ballard, ED; Freston, JW; Huang, B; Jackson, RL, 2002)
"Although relatively rare, GERD patients refractory to medical therapy remain a challenge for the clinician."	2.40	Medical therapy. Management of the refractory patient. ( Castell, DO; Hatlebakk, JG; Katz, PO, 1999)
"Reflux esophagitis is a chronic condition and after stopping antisecretory treatment, including lansoprazole, most patients relapse in terms of symptoms and endoscopical lesions, which suggests the need for long-term treatment."	2.38	Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. ( Di Fede, F; Dobrilla, G, 1993)
"A total of 207 symptomatic GERD patients, which were confirmed by endoscopy from July 2008 till January 2009, were enrolled."	1.36	[Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients]. ( Choi, TH; Hwang, JH; Hwang, TJ; Jeong, SH; Jeong, YJ; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Nah, JC; Park, YS; Song, IS, 2010)
"The hazard ratios of symptomatic recurrence of GERD in IMs and PMs compared with RMs were 0."	1.35	CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. ( Furuta, T; Hishida, A; Ikuma, M; Kimura, M; Kodaira, C; Nishino, M; Shirai, N; Sugimoto, M; Umemura, K; Watanabe, H; Yamade, M, 2009)
"Gastroesophageal reflux disease (GERD) is commonly associated with asthma; however, frequency in nonatopic children with asthmatic symptoms is unknown."	1.33	Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. ( Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H, 2006)
"The other two approaches prevent more recurrences: waiting to initiate maintenance therapy until symptoms recur once requires an additional $73 for each recurrence prevented whereas maintenance PPI from the outset requires an additional $819 for each recurrence prevented."	1.30	Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. ( Harris, RA; Kuppermann, M; Richter, JE, 1997)
"If patients experience a symptomatic recurrence on the H2RA strategies, they then receive PPI maintenance."	1.30	Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. ( Harris, RA; Kuppermann, M; Richter, JE, 1997)

Research

Studies (78)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	40 (51.28)	18.2507
2000's	27 (34.62)	29.6817
2010's	10 (12.82)	24.3611
2020's	1 (1.28)	2.80

Authors	Studies
Mizokami, Y	2
Oda, K	2
Funao, N	2
Nishimura, A	4
Soen, S	1
Kawai, T	2
Ashida, K	5
Sugano, K	2
Matsumoto, Y	1
Iwakiri, K	3
Hiramatsu, N	2
Sakurai, Y	2
Hori, T	2
Kudou, K	2
Umegaki, E	2
Wong, GLH	1
Lau, LHS	1
Ching, JYL	1
Tse, YK	1
Ling, RHY	1
Wong, VWS	1
Chiu, PWY	1
Lau, JYW	1
Chan, FKL	1
Morgan, DR	1
Torres, J	1
Sexton, R	1
Herrero, R	1
Salazar-Martínez, E	1
Greenberg, ER	1
Bravo, LE	1
Dominguez, RL	1
Ferreccio, C	1
Lazcano-Ponce, EC	1
Meza-Montenegro, MM	1
Peña, EM	1
Peña, R	1
Correa, P	1
Martínez, ME	1
Chey, WD	2
Valdivieso, M	1
Anderson, GL	1
Goodman, GE	1
Crowley, JJ	1
Baker, LH	1
Yamamoto, E	1
Brito, HS	1
Ogata, SK	1
Machado, RS	1
Kawakami, E	1
Furuta, T	2
Sugimoto, M	1
Kodaira, C	1
Nishino, M	1
Yamade, M	1
Ikuma, M	1
Shirai, N	1
Watanabe, H	1
Umemura, K	1
Kimura, M	2
Hishida, A	1
Freston, JW	2
Hisada, M	1
Peura, DA	1
Haber, MM	1
Kovacs, TO	3
Atkinson, S	1
Hunt, B	1
Hirschowitz, BI	1
Fineberg, N	1
Wilcox, CM	1
Mohnen, J	1
Worthington, J	1
Jeong, YJ	1
Lee, DH	1
Choi, TH	1
Hwang, TJ	1
Lee, BH	1
Nah, JC	1
Lee, SH	1
Park, YS	1
Hwang, JH	1
Kim, JW	1
Jeong, SH	1
Kim, N	1
Jung, HC	1
Song, IS	1
Basu, PP	1
Rayapudi, K	1
Pacana, T	1
Shah, NJ	1
Krishnaswamy, N	1
Flynn, M	1
Adachi, K	1
Furuta, K	1
Miwa, H	2
Oshima, T	1
Miki, M	1
Komazawa, Y	1
Koike, T	2
Shimatani, T	1
Kinoshita, Y	1
Abraham, D	1
Saltoun, CA	1
Lauritsen, K	1
Devière, J	1
Bigard, MA	2
Bayerdörffer, E	1
Mózsik, G	1
Murray, F	1
Kristjánsdóttir, S	1
Savarino, V	1
Vetvik, K	1
De Freitas, D	1
Orive, V	1
Rodrigo, L	1
Fried, M	2
Morris, J	1
Schneider, H	1
Eklund, S	1
Larkö, A	1
Asaka, M	3
Kato, M	2
Sugiyama, T	2
Satoh, K	1
Kuwayama, H	1
Fukuda, Y	3
Fujioka, T	1
Takemoto, T	2
Kimura, K	1
Shimoyama, T	4
Shimizu, K	1
Kobayashi, S	1
Fedele, E	1
Oderda, G	1
Marinello, D	1
Lerro, P	1
Kuvidi, M	1
de'Angelis, GL	1
Ferzetti, A	1
Cucchiara, S	1
Franco, MT	1
Romano, C	1
Strisciuglio, P	1
Pensabene, L	1
Arkkila, PE	1
Seppälä, K	1
Kosunen, TU	1
Sipponen, P	1
Mäkinen, J	1
Rautelin, H	1
Färkkilä, M	1
Feng, LY	1
Yao, XX	1
Jiang, SL	1
Dohmen, W	2
Fuchs, W	2
Yüksel, H	1
Yilmaz, O	1
Kirmaz, C	1
Aydoğdu, S	1
Kasirga, E	1
Mine, S	1
Iida, T	1
Tabata, T	1
Kishikawa, H	1
Tanaka, Y	1
Littner, MR	1
Leung, FW	1
Ballard, ED	2
Huang, B	2
Samra, NK	1
Lai, KC	2
Chu, KM	2
Hui, WM	2
Wong, BC	2
Hu, WH	2
Wong, WM	2
Chan, AO	2
Wong, J	2
Lam, SK	2
Kawamura, M	1
Ohara, S	1
Iijima, K	1
Suzuki, H	1
Kayaba, S	1
Noguchi, K	1
Abe, S	1
Noguchi, M	1
Shimosegawa, T	1
Munakata, A	1
Mizuki, I	1
Akagi, T	1
Fukuda, S	1
Ohkawa, K	1
Yoshida, Y	1
Aisawa, T	1
Sakata, Y	1
Fukushi, M	1
Yamamoto, I	1
Okui, M	1
Tonokatsu, Y	2
Asaki, S	2
Sato, A	1
Sakurada, H	1
Takeda, T	1
Hongo, M	1
Toyota, T	1
Hoshino, E	1
Umeda, N	1
Sano, J	1
Miki, K	1
Yahagi, N	1
Oka, M	1
Miyashita, H	1
Mine, T	2
Yasuda, H	1
Akimoto, K	1
Katoaka, A	1
Mashima, H	1
Tajima, A	1
Fukujin, H	1
Tsuchida, T	1
Takano, T	1
Nagasawa, J	1
Ohashi, T	1
Sakata, J	1
Haraguchi, Y	1
Eto, T	1
Avner, DL	1
Movva, R	1
Nelson, KJ	1
McFarland, M	1
Berry, W	1
Erfling, W	1
Michel, P	1
Duhamel, C	1
Bazin, B	1
Raoul, JL	1
Person, B	1
Legoux, JL	1
Sallerin, V	1
Colin, R	1
Harada, T	1
Dobrilla, G	2
Di Fede, F	1
Robinson, M	1
Lanza, F	2
Avner, D	1
Haber, M	5
van Rensburg, CJ	1
Louw, JA	1
Girdwood, AH	1
Simjee, AE	1
Marks, IN	2
Sontag, SJ	1
Kogut, DG	1
Fleischmann, R	1
Campbell, DR	1
Richter, J	3
Swarbrick, ET	1
Gough, AL	1
Foster, CS	1
Christian, J	1
Garrett, AD	1
Langworthy, CH	1
Kudo, M	1
Sukegawa, M	1
Katagiri, M	1
Koshiyama, T	1
Kagaya, H	1
Nishikawa, K	1
Hokari, K	1
Takeda, H	1
Tsujiai, T	1
Tamura, K	1
Hazell, SL	1
Daskalopoulous, G	1
Mitchell, HM	1
Massey, D	1
Hatlebakk, JG	3
Berstad, A	2
Harris, RA	2
Kuppermann, M	2
Richter, JE	2
Chiba, N	1
Chiocca, JC	1
Salis, GB	1
Goff, J	1
Silvers, D	1
Winters, J	1
Jhala, N	1
Jennings, D	1
Greski-Rose, P	1
Russo, A	1
Dattilo, M	1
Haga, Y	1
Nakatsura, T	1
Shibata, Y	1
Sameshima, H	1
Nakamura, Y	1
Tanimura, M	1
Ogawa, M	1
King, VJ	1
Lindsetmo, RO	1
Johnsen, R	1
Revhaug, A	1
Campbell, D	2
Rose, P	3
Jennings, DE	2
Schwartz, H	1
Krause, R	1
Sahba, B	1
Weissfeld, A	1
Siepman, N	1
Freston, J	1
Suzuki, J	1
Kobayasi, I	1
Fujita, T	1
Zhang, T	1
O'Keefe, SJ	1
Winter, T	1
Ogden, J	1
Nakagawa, M	1
Ooishi, M	1
Yoda, Y	1
Kawamura, N	1
Ooizumi, H	1
Saitou, M	1
Nakagawa, S	1
Bardhan, KD	1
Crowe, J	1
Thompson, RP	1
Trewby, PN	1
Keeling, PN	1
Weir, D	1
Crouch, SL	1
Sou, Y	1
Saita, H	1
Takahashi, Y	1
Yoshinaga, T	1
Matsukawa, Y	1
Sekikawa, A	1
Nakazawa, T	1
Shio, S	1
Kohigashi, K	1
Bustamante, M	1
Stollman, N	1
Katz, PO	1
Castell, DO	1
Capurso, L	1
Di Mario, F	1
Battaglia, F	1
Dal Bò, N	1
Leandro, G	1
Benedetti, E	1
Bottona, E	1
Caroli, A	1
Costan-Biedo, F	1
De Bastiani, R	1
Germanà, B	1
Andrea Grassi, S	1
Madia, D	1
Marcon, V	1
Marin, R	1
Monica, F	1
Olivieri, P	1
Orzes, N	1
Pilotto, A	1
Ronzani, G	1
Saggioro, A	1
Tafner, G	1
Kaneko, E	1
Hoshihara, Y	1
Sakaki, N	1
Harasawa, S	1
Nakamura, T	1
Kobayashi, K	1
Kajiyama, G	1
Ogawa, N	1
Yao, T	1
Muto, Y	1
Nakazawa, S	1
Luzza, F	1
Giglio, A	1
Ciliberto, E	1
Belmonte, A	1
Cavaliere, C	1
Saccà, N	1
Frandina, C	1
Fiocca, R	1
Trimboli, V	1
Pallone, F	1
Schwizer, W	1
Thumshirn, M	1
Dent, J	1
Guldenschuh, I	1
Menne, D	1
Cathomas, G	1
Nagahara, A	1
Ohkura, R	1
Yamada, T	1
Sato, K	1
Hojo, M	1
Sato, N	1
Hawkey, GM	1
Cole, AT	1
McIntyre, AS	1
Long, RG	1
Hawkey, CJ	1
Tytgat, GN	1
Fendrick, AM	1
Jackson, RL	1
Lau, GK	1
Yuen, MF	1
Lai, CL	1
Yanai, H	1
Tada, M	1
Okita, K	1
Hotz, J	1
Kleinert, R	1
Grymbowski, T	1
Hennig, U	1
Schwarz, JA	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452750]	Phase 3	642 participants (Actual)	Interventional	2011-10-31	Completed
A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456260]	Phase 3	406 participants (Actual)	Interventional	2011-09-30	Completed
A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452763]	Phase 3	621 participants (Actual)	Interventional	2011-10-31	Completed
A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456247]	Phase 3	439 participants (Actual)	Interventional	2012-03-31	Completed
Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial[NCT01180179]	Phase 4	228 participants (Actual)	Interventional	2010-06-30	Completed
A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori[NCT01061437]	Phase 3	1,859 participants (Actual)	Interventional	2009-06-30	Completed
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466]	Phase 4	82 participants (Actual)	Interventional	2019-05-26	Terminated (stopped due to Budget for the study was withdrawn and discontinued)
Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373]	Phase 4	72 participants (Actual)	Interventional	2003-03-31	Completed
Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial[NCT04039412]	Phase 4	330 participants (Actual)	Interventional	2018-06-01	Completed
European Registry on the Management of Helicobacter Pylori Infection[NCT02328131]		10,000 participants (Anticipated)	Observational	2013-06-30	Recruiting
A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753]	Phase 4	143 participants (Actual)	Interventional	2014-01-31	Completed
Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial[NCT02903017]	Phase 4	114 participants (Actual)	Interventional	2016-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment

The Median Survival From the Time of Diagnosis.

Intervention	participants (Number)
Single Group	72

The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months

Incidence of Treatment-Emergent Adverse Events

Intervention	years (Median)
Single Group	6.6

Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events (NCT04039412)
Timeframe: 10-14 days

Percentage of Helicobacter Pylori Infection Cure

Intervention	Participants (Count of Participants)
(1) Reverse Hybrid Regimen	49
(2) Hybrid Regimen	58
(3) Levofloxacin Quadruple Regimen	44

Measuring the curative rate of each regimen by a fecal antigen test (NCT04039412)
Timeframe: 40-44 days

Rate of Helicobacter Pylori Treatment Completion

Intervention	Participants (Count of Participants)
(1) Reverse Hybrid Regimen	102
(2) Hybrid Regimen	101
(3) Levofloxacin Quadruple Regimen	91

Questionnaire to evaluate the compliance with each treatment regimen (NCT04039412)
Timeframe: 10-14 days

Article	Year
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship,	2003
[New therapy of peptic ulcer]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1995, Mar-10, Volume: 84, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alprostadil; Anti-Ulcer Agents; Histamine H2 Antagonists; H	1995
Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. Clinical therapeutics, 1993, Volume: 15 Suppl B Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Esophagitis; Gastric Acid; Gastr	1993
Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 1997, Volume: 11 Suppl B Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Lans	1997
[Gastroesophageal reflux disease refractory to medical treatment. Which approach: the pill or the scalpel?]. Acta gastroenterologica Latinoamericana, 1997, Volume: 27, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Fundoplication; Gastroesophageal Reflux; Hu	1997
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review. Journal of clinical gastroenterology, 2000, Volume: 30, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans;	2000
Medical therapy. Management of the refractory patient. Gastroenterology clinics of North America, 1999, Volume: 28, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Gastroesophag	1999
[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. Recenti progressi in medicina, 2000, Volume: 91, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;	2000
Review article: long-term use of proton pump inhibitors in GORD--help or hindrance? Alimentary pharmacology & therapeutics, 2001, Volume: 15 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Lansopr	2001
Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs, 2002, Volume: 62, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Esophagitis; H	2002

Article	Year
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T	2018
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T	2018
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T	2018
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Equivalence T	2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double	2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double	2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double	2018
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut, 2018, Volume: 67, Issue:6 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double	2018
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World journal of gastroenterology, 2018, Apr-14, Volume: 24, Issue:14 Topics: Adult; Aged; Biopsy; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; Gas	2018
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. Gut, 2020, Volume: 69, Issue:4 Topics: Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antag	2020
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA, 2013, Feb-13, Volume: 309, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath	2013
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Alimentary pharmacology & therapeutics, 2016, Volume: 43, Issue:2 Topics: Adult; Aged; Cytochrome P-450 CYP2C19; Double-Blind Method; Esophagitis; Female; Humans; Lansoprazol	2016
The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Alimentary pharmacology & therapeutics, 2009, Jun-15, Volume: 29, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagi	2009
Costs and risks in the management of patients with gastric acid hypersecretion. Journal of clinical gastroenterology, 2010, Volume: 44, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Endoscop	2010
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. The American journal of gastroenterology, 2011, Volume: 106, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent	2011
A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease. Digestive diseases and sciences, 2012, Volume: 57, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Alanine; Dose-Response Rela	2012
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship,	2003
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Journal of gastroenterology, 2003, Volume: 38, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer	2003
Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial. Helicobacter, 2004, Volume: 9, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Breath Tests; Child; Double-Blind	2004
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent	2005
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial. World journal of gastroenterology, 2005, Feb-21, Volume: 11, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent	2005
Management of symptoms in step-down therapy of gastroesophageal reflux disease. Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit	2005
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest, 2005, Volume: 128, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adrenal Cortex Hormones; Adult;	2005
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. The American journal of medicine, 2005, Volume: 118, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-	2005
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office]. MMW Fortschritte der Medizin, 2005, Apr-07, Volume: 147 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Dose-Re	2005
Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrom	2007
Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. Journal of clinical gastroenterology, 1995, Volume: 20 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D	1995
Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. Journal of clinical gastroenterology, 1995, Volume: 20 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-	1995
Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group. Journal of clinical gastroenterology, 1995, Volume: 20 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Atrophy; Duodenal Ulcer; Gastric Mucosa;	1995
Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration? Journal of clinical gastroenterology, 1995, Volume: 20 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Administration Schedule; Duo	1995
The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody. Journal of clinical gastroenterology, 1995, Volume: 20 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antibodi	1995
Effect of lansoprazole on peptic ulcers. Journal of clinical gastroenterology, 1995, Volume: 20 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Female; Helicobacter Inf	1995
Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer. The American journal of gastroenterology, 1995, Volume: 90, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Admini	1995
[Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study]. Gastroenterologie clinique et biologique, 1994, Volume: 18, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B	1994
Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Annals of internal medicine, 1996, May-15, Volume: 124, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esopha	1996
A trial of lansoprazole in refractory gastric ulcer. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Anti-Ulcer Agents; Drug Resistanc	1996
Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group. The American journal of gastroenterology, 1996, Volume: 91, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Enzy	1996
Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine. European journal of gastroenterology & hepatology, 1996, Volume: 8, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dilatation; Double-Blind Method; Drug Ad	1996
Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Ulcer	1996
Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection. Journal of gastroenterology and hepatology, 1997, Volume: 12, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Bli	1997
Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me	1997
Prevention of duodenal ulcer recurrence with 15 mg lansoprazole: a double-blind placebo-controlled study. The Lansoprazole Study Group. Digestive diseases and sciences, 1997, Volume: 42, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Biopsy; Double-Blind Method	1997
Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial. Italian journal of gastroenterology and hepatology, 1997, Volume: 29, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bed Rest; Dose-	1997
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy. Scandinavian journal of gastroenterology, 1998, Volume: 33, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer	1998
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer. Digestive diseases and sciences, 1998, Volume: 43, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biopsy; Cell Count; Double-Blind Method;	1998
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. The American journal of gastroenterology, 1998, Volume: 93, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer	1998
Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis; G	1997
Effect of chronic duodenal ulceration and its treatment with lanzoprazole or sucralfate on gastroduodenal mucosal protein turnover and TGF-alpha, bFGF, and EGF receptor expression in humans. Digestive diseases and sciences, 1998, Volume: 43, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Chronic Disease; Duodenal Ulcer;	1998
[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer]. Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Admini	1999
Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Me	1999
Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo as maintenance therapy in patients with healed duodenal ulcers resistant to H2-receptor antagonists. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug R	1999
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study). Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2000, Volume: 32, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin;	2000
Peptic ulcer recurrence during maintenance therapy with H2-receptor antagonist following first-line therapy with proton pump inhibitor. Journal of gastroenterology, 2000, Volume: 35, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Female; Histamine	2000
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. Clinical therapeutics, 2001, Volume: 23, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit	2001
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet (London, England), 2001, Jun-02, Volume: 357, Issue:9270 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; A	2001
Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Gut, 2001, Volume: 49, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antifibrinolytic Agents; Blood Transfusi	2001
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. The New England journal of medicine, 2002, Jun-27, Volume: 346, Issue:26 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A	2002
Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. Alimentary pharmacology & therapeutics, 1992, Volume: 6, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duoden	1992

Article	Year
High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents. Journal of pediatric gastroenterology and nutrition, 2014, Volume: 59, Issue:5 Topics: Adolescent; Anti-Ulcer Agents; Body Mass Index; Child; Child, Preschool; Endoscopy; Esophagitis; Eso	2014
CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. European journal of clinical pharmacology, 2009, Volume: 65, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cli	2009
[Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 55, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Follow-Up Studies;	2010
Facial swelling and eosinophilia in a 44-year-old woman. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2002, Volume: 89, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Angioedema; Cefuroxime; Cetirizine; Diagnosis, Diffe	2002
[Is gastric and duodenal ulcer drug-treatable or surgical disease?]. Chirurgia italiana, 1997, Volume: 49, Issue:1-2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Humans; Lansoprazole; Om	1997
[Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office]. MMW Fortschritte der Medizin, 2005, Mar-03, Volume: 147, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis, Peptic; Humans; Lansoprazol	2005
Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. Respiratory medicine, 2006, Volume: 100, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Child; Ch	2006
Eradication of Helicobacter pylori followed by reinfection. Journal of gastroenterology, 1996, Volume: 31 Suppl 9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Blot	1996
Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. The American journal of medicine, 1997, Volume: 102, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cost-Benefit Analysis; Esophagitis, Pept	1997
Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Case-Control Studies; Cost-Benefit Analy	1997
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Digestive diseases and sciences, 1998, Volume: 43, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Hist	1998
PPIs vs H2RAs for erosive reflux esophagitis. The Journal of family practice, 1998, Volume: 46, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Cost-Benefit Analysis; Enzyme Inhibitors; Es	1998
Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer. Journal of clinical gastroenterology, 1998, Volume: 27 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer	1998
Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients. Journal of gastroenterology, 1999, Volume: 34 Suppl 11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent	1999
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection. Journal of gastroenterology and hepatology, 2001, Volume: 16, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent	2001
Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice. Archives of internal medicine, 2001, Sep-24, Volume: 161, Issue:17 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Br	2001
[Proton pump inhibitor for maintenance therapy of peptic ulcer]. Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Endoscopy, Gastrointestinal; H(+	1992

lansoprazole and Recrudescence